NCT04727580

HSK7653 in Chinese Patients with Impaired Glucose Tolerance

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Clinical Trial to Study the Efficacy and Safety of HSK7653 in Chinese Patients with Impaired Glucose Tolerance

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.

Conditions

• Impaired Glucose Tolerance

Interventions

Type	Name	Description
DRUG	HSK7653 10mg Q2W	HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
DRUG	HSK7653 25mg Q2W	HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
DRUG	Placebo	Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

Timeline

• Start date: 2021-03-29
• Primary completion: 2022-06-12
• Completion: 2022-06-29
• First posted: 2021-01-27
• Last updated: 2024-11-25

Locations

1 site across 1 country: China